Anti-Obesity Drugs Market is expected to reach US$ 5.95 Bn by 2030 from US$ 2.22 Bn in 2023, at a CAGR of 15.1% during the forecast period.Anti-Obesity Drugs Market Overview:
Anti-obesity drugs are medications, which are used to reduce body weight by lowering cholesterol levels in the body. These drugs affect the human body's basic functions by modifying appetite or eating calories.To know about the Research Methodology :- Request Free Sample ReportGlobal Anti-Obesity Drugs Market Dynamics:
The rising prevalence of obesity worldwide is the major factor driving the market growth. The anti-obesity drugs market is expected to rise due to the rising cases of obesity and overweight among patients worldwide as a result of inactive lifestyles and bad eating habits. The World Health Organization (WHO) estimates that over 1.8 billion adults aged 18 and above were overweight in 2017. The leading players in the industry are also undergoing product creation and finding market approvals as a result of the rise in the global obesity population. In 2023, Novo Nordisk formed an alliance with Evotec AG to discover and produce drug molecules to treat a variety of metabolic disorders, such as obesity, diabetes, and other related illnesses. The increasing need for medicines that have long-term effects is expected to create enormous opportunities for market vendors to develop new products. This factor is expected to eventually aid the market growth. The rising prevalence of obesity, as well as type II diabetes, has prompted many market analysts and vendors to conduct studies on drugs that can treat both obesity and type II diabetes. MED10382 by AstraZeneca and Bimagrumab by Novartis are two of the medicines being tested for obesity and type II diabetes. However, drug side effects and the lack of combination therapy are expected to limit the market's growth. Along with this, the market for anti-obesity drugs is expected to be hampered by the rising acceptance of alternative alternatives such as gyms, exercise spas, treatments to minimise obesity, patient compliance for surgical procedures, and a high change in diet plan. Furthermore, the launch of new anti-obesity drugs, as well as untapped opportunities in emerging markets, would boost demand growth over the forecast period. The report has profiled fifteen key players in the market from different regions. However, the report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for a future hot spot in APAC region.Global Anti-Obesity Drugs Market Segment Analysis:
The Global Anti-Obesity Drugs Market is segmented on the basis of Mechanism of Action, Drug Type and Distribution Channel. Based on Drug Type, the Prescription Drugs segment is expected to hold the dominant market share during the forecast period. The easy availability of therapeutically effective anti-obesity drugs in the market is credited with the segment's rapid growth. The increasing consumption of junk food is causing global population health to deteriorate, leading to an increase in the prevalence of obesity, especially in developing countries.Anti-Obesity Drugs Market, by Mechanism of Action in 2023(%)
Global Anti-Obesity Drugs Market Regional Insights:
North America is expected to account for the largest market share during the forecast period. North America is expected to hold a dominant market share during the forecast period, owing to the increase in the obese population and high healthcare expenditure are the primary factors driving the market's growth. The Centres for Disease Control and Prevention (CDC) states that adult obesity prevalence is growing owing to current circumstances of work from home, less physical activity, and financial and other stress among the adult population which contributes to the market growth in the region. The Asia Pacific is expected to witness the highest growth during the forecast period. The factors contributing to the market growth in the region are the rising consumer disposable income, rise in healthcare expenses, and the increasing prevalence of obesity and both type I and type II diabetes. Also, the increasing demand for drugs and rising awareness about anti-obesity drugs in Asia Pacific countries such as India, China and South Korea will also contribute to the region's anti-obesity drugs market growth. The report also helps in understanding the Global Anti-Obesity Drugs Market dynamics, structure by analyzing the market segments and project the Global Anti-Obesity Drugs Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Anti-Obesity Drugs Market make the report investor’s guide.Global Anti-Obesity Drugs Market, Key Developments:
• In January 2022, Novo Nordisk AS announced a collaboration with the start-up Fauna Bio to study the molecules and pathways that control metabolism in hibernating animals in order to find new therapeutic approaches to obesity. • Saxenda, Novo Nordisk's anti-obesity drug, was approved by the US Food and Drug Administration (FDA) in December 2020 for the treatment of obesity in adolescents aged 12 to 17. • Eisai Inc. reported in February 2019 that the United States Food and Drug Administration (FDA) had approved its latest supplementary drug application. BELVIQ, the company's anti-obesity drug, will have its labeling updated as a result of this.Global Anti-Obesity Drugs Market Scope: Inquire before buying
Global Anti-Obesity Drugs Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: US $ 2.22 Bn. Forecast Period 2024 to 2030 CAGR: 15.1% Market Size in 2030: US $ 5.95 Bn. Segments Covered: by Mechanism of Action Peripherally Acting Drugs Centrally Acting Drugs by Drug Type Prescription Drugs OTC Drugs by Distribution Channel Hospitals Pharmacies Retail Pharmacies E-commerce Global Anti-Obesity Drugs Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe) Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina, Columbia and Rest of South America)Global Anti-Obesity Drugs Market, Key Players are
North America 1. Icahn Enterprises 2. Pfizer 3. Orexigen Therapeutics 4. Bristol-Myers Squibb Europe 5. Novo Nordisk 6. Roche 7. Norgine 8. GSK 9. Saniona 10. AstraZeneca 11. Hikma Pharmaceuticals APAC 12. Eisai 13. Takeda Pharmaceutical Company 14. Sanofi India 15. Sun Pharmaceutical Industries 16. Teijin Pharma 17. Kowa 18. Cipla 19. Torrent Pharmaceuticals 20. Zydus Lifesciences 21. Glenmark Pharmaceuticals Middle East 22. Teva Pharmaceutical Industries 23. Gulf Pharmaceutical Industries 24. Saudi Pharmaceutical Industries & Medical Appliances 25. The Jordanian Pharmaceutical Manufacturing Company South America 26. Eurofarma Laboratorios Frequently Asked Questions: 1. Which region has the largest share in Global Anti-Obesity Drugs Market? Ans: North America region holds the highest share in 2023. 2. What is the growth rate of Global Anti-Obesity Drugs Market? Ans: The Global Anti-Obesity Drugs Market is growing at a CAGR of 15.1% during forecasting period 2024-2030. 3. What is scope of the Global Anti-Obesity Drugs market report? Ans: Global Anti-Obesity Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Anti-Obesity Drugs market? Ans: The important key players in the Global Market are – Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., GlaxoSmithKline PLC, F. Hoffmann-La Roche, Shionogi Inc., Norgine B.V., Pfizer Inc., and Zafgen. 5. What is the study period of this market? Ans: The Global Market is studied from 2023 to 2030.
1. Anti-Obesity Drugs Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Anti-Obesity Drugs Market: Dynamics 2.1. Anti-Obesity Drugs Market Trends by Region 2.1.1. North America Anti-Obesity Drugs Market Trends 2.1.2. Europe Anti-Obesity Drugs Market Trends 2.1.3. Asia Pacific Anti-Obesity Drugs Market Trends 2.1.4. Middle East and Africa Anti-Obesity Drugs Market Trends 2.1.5. South America Anti-Obesity Drugs Market Trends 2.2. Anti-Obesity Drugs Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Anti-Obesity Drugs Market Drivers 2.2.1.2. North America Anti-Obesity Drugs Market Restraints 2.2.1.3. North America Anti-Obesity Drugs Market Opportunities 2.2.1.4. North America Anti-Obesity Drugs Market Challenges 2.2.2. Europe 2.2.2.1. Europe Anti-Obesity Drugs Market Drivers 2.2.2.2. Europe Anti-Obesity Drugs Market Restraints 2.2.2.3. Europe Anti-Obesity Drugs Market Opportunities 2.2.2.4. Europe Anti-Obesity Drugs Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Anti-Obesity Drugs Market Drivers 2.2.3.2. Asia Pacific Anti-Obesity Drugs Market Restraints 2.2.3.3. Asia Pacific Anti-Obesity Drugs Market Opportunities 2.2.3.4. Asia Pacific Anti-Obesity Drugs Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Anti-Obesity Drugs Market Drivers 2.2.4.2. Middle East and Africa Anti-Obesity Drugs Market Restraints 2.2.4.3. Middle East and Africa Anti-Obesity Drugs Market Opportunities 2.2.4.4. Middle East and Africa Anti-Obesity Drugs Market Challenges 2.2.5. South America 2.2.5.1. South America Anti-Obesity Drugs Market Drivers 2.2.5.2. South America Anti-Obesity Drugs Market Restraints 2.2.5.3. South America Anti-Obesity Drugs Market Opportunities 2.2.5.4. South America Anti-Obesity Drugs Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Anti-Obesity Drugs Industry 2.8. Analysis of Government Schemes and Initiatives For Anti-Obesity Drugs Industry 2.9. Anti-Obesity Drugs Market Trade Analysis 2.10. The Global Pandemic Impact on Anti-Obesity Drugs Market 3. Anti-Obesity Drugs Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2023-2030 3.1. Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 3.1.1. Peripherally Acting Drugs 3.1.2. Centrally Acting Drugs 3.2. Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 3.2.1. Prescription Drugs 3.2.2. OTC Drugs 3.3. Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 3.3.1. Hospitals Pharmacies 3.3.2. Retail Pharmacies 3.3.3. E-commerce 3.4. Anti-Obesity Drugs Market Size and Forecast, by Region (2023-2030) 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Middle East and Africa 3.4.5. South America 4. North America Anti-Obesity Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 4.1. North America Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 4.1.1. Peripherally Acting Drugs 4.1.2. Centrally Acting Drugs 4.2. North America Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 4.2.1. Prescription Drugs 4.2.2. OTC Drugs 4.3. North America Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 4.3.1. Hospitals Pharmacies 4.3.2. Retail Pharmacies 4.3.3. E-commerce 4.4. North America Anti-Obesity Drugs Market Size and Forecast, by Country (2023-2030) 4.4.1. United States 4.4.1.1. United States Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 4.4.1.1.1. Peripherally Acting Drugs 4.4.1.1.2. Centrally Acting Drugs 4.4.1.2. United States Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 4.4.1.2.1. Prescription Drugs 4.4.1.2.2. OTC Drugs 4.4.1.3. United States Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 4.4.1.3.1. Hospitals Pharmacies 4.4.1.3.2. Retail Pharmacies 4.4.1.3.3. E-commerce 4.4.2. Canada 4.4.2.1. Canada Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 4.4.2.1.1. Peripherally Acting Drugs 4.4.2.1.2. Centrally Acting Drugs 4.4.2.2. Canada Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 4.4.2.2.1. Prescription Drugs 4.4.2.2.2. OTC Drugs 4.4.2.3. Canada Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 4.4.2.3.1. Hospitals Pharmacies 4.4.2.3.2. Retail Pharmacies 4.4.2.3.3. E-commerce 4.4.3. Mexico 4.4.3.1. Mexico Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 4.4.3.1.1. Peripherally Acting Drugs 4.4.3.1.2. Centrally Acting Drugs 4.4.3.2. Mexico Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 4.4.3.2.1. Prescription Drugs 4.4.3.2.2. OTC Drugs 4.4.3.3. Mexico Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 4.4.3.3.1. Hospitals Pharmacies 4.4.3.3.2. Retail Pharmacies 4.4.3.3.3. E-commerce 5. Europe Anti-Obesity Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 5.1. Europe Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 5.2. Europe Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 5.3. Europe Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 5.4. Europe Anti-Obesity Drugs Market Size and Forecast, by Country (2023-2030) 5.4.1. United Kingdom 5.4.1.1. United Kingdom Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 5.4.1.2. United Kingdom Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 5.4.1.3. United Kingdom Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel(2023-2030) 5.4.2. France 5.4.2.1. France Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 5.4.2.2. France Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 5.4.2.3. France Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel(2023-2030) 5.4.3. Germany 5.4.3.1. Germany Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 5.4.3.2. Germany Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 5.4.3.3. Germany Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.4. Italy 5.4.4.1. Italy Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 5.4.4.2. Italy Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 5.4.4.3. Italy Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel(2023-2030) 5.4.5. Spain 5.4.5.1. Spain Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 5.4.5.2. Spain Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 5.4.5.3. Spain Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.6. Sweden 5.4.6.1. Sweden Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 5.4.6.2. Sweden Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 5.4.6.3. Sweden Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.7. Austria 5.4.7.1. Austria Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 5.4.7.2. Austria Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 5.4.7.3. Austria Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.8. Rest of Europe 5.4.8.1. Rest of Europe Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 5.4.8.2. Rest of Europe Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 5.4.8.3. Rest of Europe Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 6. Asia Pacific Anti-Obesity Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 6.1. Asia Pacific Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 6.2. Asia Pacific Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 6.3. Asia Pacific Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 6.4. Asia Pacific Anti-Obesity Drugs Market Size and Forecast, by Country (2023-2030) 6.4.1. China 6.4.1.1. China Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 6.4.1.2. China Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 6.4.1.3. China Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.2. S Korea 6.4.2.1. S Korea Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 6.4.2.2. S Korea Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 6.4.2.3. S Korea Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.3. Japan 6.4.3.1. Japan Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 6.4.3.2. Japan Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 6.4.3.3. Japan Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.4. India 6.4.4.1. India Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 6.4.4.2. India Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 6.4.4.3. India Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.5. Australia 6.4.5.1. Australia Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 6.4.5.2. Australia Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 6.4.5.3. Australia Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.6. Indonesia 6.4.6.1. Indonesia Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 6.4.6.2. Indonesia Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 6.4.6.3. Indonesia Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.7. Malaysia 6.4.7.1. Malaysia Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 6.4.7.2. Malaysia Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 6.4.7.3. Malaysia Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.8. Vietnam 6.4.8.1. Vietnam Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 6.4.8.2. Vietnam Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 6.4.8.3. Vietnam Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel(2023-2030) 6.4.9. Taiwan 6.4.9.1. Taiwan Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 6.4.9.2. Taiwan Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 6.4.9.3. Taiwan Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.10. Rest of Asia Pacific 6.4.10.1. Rest of Asia Pacific Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 6.4.10.2. Rest of Asia Pacific Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 6.4.10.3. Rest of Asia Pacific Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 7. Middle East and Africa Anti-Obesity Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 7.1. Middle East and Africa Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 7.2. Middle East and Africa Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 7.3. Middle East and Africa Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 7.4. Middle East and Africa Anti-Obesity Drugs Market Size and Forecast, by Country (2023-2030) 7.4.1. South Africa 7.4.1.1. South Africa Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 7.4.1.2. South Africa Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 7.4.1.3. South Africa Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 7.4.2. GCC 7.4.2.1. GCC Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 7.4.2.2. GCC Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 7.4.2.3. GCC Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 7.4.3. Nigeria 7.4.3.1. Nigeria Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 7.4.3.2. Nigeria Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 7.4.3.3. Nigeria Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 7.4.4. Rest of ME&A 7.4.4.1. Rest of ME&A Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 7.4.4.2. Rest of ME&A Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 7.4.4.3. Rest of ME&A Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 8. South America Anti-Obesity Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 8.1. South America Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 8.2. South America Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 8.3. South America Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel(2023-2030) 8.4. South America Anti-Obesity Drugs Market Size and Forecast, by Country (2023-2030) 8.4.1. Brazil 8.4.1.1. Brazil Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 8.4.1.2. Brazil Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 8.4.1.3. Brazil Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 8.4.2. Argentina 8.4.2.1. Argentina Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 8.4.2.2. Argentina Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 8.4.2.3. Argentina Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 8.4.3. Rest Of South America 8.4.3.1. Rest Of South America Anti-Obesity Drugs Market Size and Forecast, by Mechanism of Action (2023-2030) 8.4.3.2. Rest Of South America Anti-Obesity Drugs Market Size and Forecast, by Drug Type (2023-2030) 8.4.3.3. Rest Of South America Anti-Obesity Drugs Market Size and Forecast, by Distribution Channel (2023-2030) 9. Global Anti-Obesity Drugs Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Anti-Obesity Drugs Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Icahn Enterprises 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Pfizer 10.3. Orexigen Therapeutics 10.4. Bristol-Myers Squibb 10.5. Novo Nordisk 10.6. Roche 10.7. Norgine 10.8. GSK 10.9. Saniona 10.10. AstraZeneca 10.11. Hikma Pharmaceuticals 10.12. Eisai 10.13. Takeda Pharmaceutical Company 10.14. Sanofi India 10.15. Sun Pharmaceutical Industries 10.16. Teijin Pharma 10.17. Kowa 10.18. Cipla 10.19. Torrent Pharmaceuticals 10.20. Zydus Lifesciences 10.21. Glenmark Pharmaceuticals 10.22. Teva Pharmaceutical Industries 10.23. Gulf Pharmaceutical Industries 10.24. Saudi Pharmaceutical Industries & Medical Appliances 10.25. The Jordanian Pharmaceutical Manufacturing Company 10.26. Eurofarma Laboratorios 11. Key Findings 12. Industry Recommendations 13. Anti-Obesity Drugs Market: Research Methodology 14. Terms and Glossary